JPRN-UMIN000014707
Completed
Phase 2
Efficacy and safety of neoadjuvant chemotherapy by S-1 plus cisplatin for Stage III esophageal squamous cell carcinoma: A phase II trial - Neoadjuvant chemotherapy by S-1 plus cisplatin for esophageal squamous cell carcinoma
agoya University Hospital0 sites30 target enrollmentJuly 30, 2014
ConditionsEsophageal squamous cell carcinoma
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Esophageal squamous cell carcinoma
- Sponsor
- agoya University Hospital
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ 2\) Uncontrolled infection 3\) Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers 4\) Psychiatric disease 5\) Continuous systemic steroid therapy 6\) Uncontrolled severe complications (DM, hypertension, diarrhea, et al.) 7\) Patient with symptomatic cardiovascular disease or asymptomatic disease but have been treated 8\) Symptomatic CNS metastasis 9\) Interstitial lung disease or pulmonary fibrosis 10\) Hypersensitivity for S\-1 or cisplatin 11\) Flucytosine, phenytoin, warfarin potassium or aminoglycoside antibiotic administration 12\) Intestinal bleeding 13\) Judged by physician inadequate for inclusion in this trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 3
Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)cholangiocarcinomamuscle invasive gallbladder carcinomaCancer - Biliary tree (gall bladder and bile duct)ACTRN12615001283561Australasian Gastro-Intestinal Trials Group32
Recruiting
N/A
Prospective study of neoadjuvant chemotherapy with FEC100x4 for BRCAness cases in triple negative breast cancerBreast cancerJPRN-UMIN000029433Tokyo medical university70
Completed
N/A
Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility multicenter study(1) breast cancer with histological confirmation(2) stage II or III breast cancer and previous standard anthracycline and/or taxane-based PSC, followed by curative surgery(3) age 20-75 years(4) Eastern Cooperative Oncology Group performance status 0,1(5) adequate gastrointestinal function(6) adequate organ functionJPRN-UMIN000013469Saitama Medical University International Medical Center40
Recruiting
Phase 2
eoadjuvant chemotherapy in NSCLCHealth Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lungHealth Condition 2: null- stage 2b and 3 Non Small Cell Lung CancerCTRI/2016/05/006916investigator initiated study
Completed
N/A
Prospective study of neoadjuvant chemotherapy for HER2 positive breast cancer.JPRN-UMIN000046338Sapporo Medical University24